细胞内胺β和阿波利波蛋白-E之间的毒性相互作用
Arpan Dey1, Aditi Verma1, Uchit Bhaskar2
1Department of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai 400005, India.
ACS chemical neuroscience
|February 29, 2024
概括
脂蛋白E (ApoE) 变体通过改变细胞内的粉样β (Aβ) 寡合物特性来影响阿尔茨海默病 (AD) 风险. 准Aβ-ApoE相互作用为AD提供了一个潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 的发病过程涉及粉样β (Aβ) 和蛋白聚合.
- 脂蛋白E (ApoE) 变体是阿尔茨海默病的关键遗传风险因素,但它们的确切作用,特别是细胞内作用,尚不清楚.
研究的目的:
- 在AD的背景下,研究Aβ寡合体和ApoE之间的细胞内相互作用.
- 确定ApoE如何影响Aβ寡合物的特性和毒性.
- 探索Aβ-ApoE相互作用作为AD药物发现的目标的潜力.
主要方法:
- 在老鼠大脑细胞中利用光标记的Aβ寡合体的光寿命测量.
- 采用单分子技术来分析寡合体构造和石化学.
- 评估了Aβ-ApoE相互作用抑制剂对Aβ毒性的影响.
- 检查了来自阿尔茨海默病患者iPSCs的神经干细胞.
主要成果:
- 细胞ApoE含量与Aβ寡合体光寿命的特定变化相关.
- 抑制Aβ-ApoE相互作用以剂量依赖的方式降低了Aβ毒性.
- 单分子分析显示,由于 ApoE 相互作用,Aβ 寡合体构造和石基度发生变化.
- 在阿尔茨海默氏症患者衍生的神经干细胞中观察到类似的光寿命变化.
结论:
- 细胞内 ApoE 相互作用改变 Aβ 寡合体,影响它们的 N 末端,静态度,膜亲和力和毒性.
- 这些ApoE诱导的Aβ寡合体的变化可以在活细胞中成像.
- 观察到的现象为阿尔茨海默病药物发现的快速定量细胞测试提供了潜在的基础.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
11.9K
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
